Downtrend on the daily chart: below its 50- and 200-day averages · 50-day above the 200-day · SuperTrend down since Sep 25 · below the Ichimoku cloud · RSI 29 (oversold) · MACD below its signal
None of the 29 investors followed here reported a position in IMMX in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a IMMX trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| May 21, 2026 | Adams Helen CDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| May 21, 2026 | Chang Nancy TDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| May 21, 2026 | Buchan Melissa JaneDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| May 21, 2026 | Marquet MagdaDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| May 21, 2026 | Ng CareyDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| May 21, 2026 | Hsu JasonDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| May 21, 2026 | Chudnovsky YekaterinaDirector | Stock Award(Grant) at price 0.00 per share. | 6.3K | — |
| Dec 9, 2025 | Rachman Ilya MChief Executive Officer | Purchase at price 6.67 per share. | 746 | $4.98K |
| Dec 9, 2025 | Morris Gabriel SChief Financial Officer | Purchase at price 6.58 per share. | 770 | $5.07K |
| Dec 7, 2025 | Morris Gabriel SChief Financial Officer | Conversion of Exercise of derivative security at price 0.80 per share. | 156K | $124.80K |
| Sep 16, 2025 | Rachman Ilya MChief Executive Officer | Purchase at price 2.02 per share. | 2.5K | $5.05K |
| Sep 15, 2025 | Morris Gabriel SChief Financial Officer | Purchase at price 1.97 per share. | 2.6K | $5.12K |
| Jun 17, 2025 | Rachman Ilya MChief Executive Officer | Purchase at price 2.30 per share. | 2.2K | $5.00K |
| Jun 17, 2025 | Morris Gabriel SChief Financial Officer | Purchase at price 2.28 per share. | 2.2K | $5.07K |
| Dec 22, 2024 | Hsu JasonDirector | Purchase at price 2.17 - 2.19 per share. | 47.7K | $104.36K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 11.5 | 38.4 | 12.9 | -2.0 | 0.8 | 14.6 | -19.3 | 68.6 | -25.8 | -16.5 | +66.2% | ||
| 2025 | -11.8 | -8.2 | -5.6 | 25.6 | 10.9 | -11.5 | 31.4 | -18.4 | -5.9 | 81.8 | 11.8 | 23.1 | +137.7% |
| 2024 | -44.8 | -12.3 | -8.4 | -29.3 | -2.8 | -6.2 | 4.5 | 3.4 | -30.4 | 7.4 | 31.9 | 4.3 | −68.2% |
| 2023 | 13.5 | -20.0 | -12.5 | 35.7 | -18.2 | 33.2 | -23.4 | -1.5 | 68.5 | 5.8 | 41.2 | 35.4 | +202.2% |
| 2022 | 14.0 | -26.6 | -19.1 | -42.7 | 55.1 | 21.5 | -6.2 | -25.4 | -25.3 | -26.5 | 21.0 | 89.3 | −35.7% |
| 2021 | — |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Buy / hold / sell counts